55 related articles for article (PubMed ID: 34139691)
1. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment.
Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(10):611-621. PubMed ID: 34139691
[TBL] [Abstract][Full Text] [Related]
2. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment.
Lin PT; Teng W; Jeng WJ; Lin CC; Lin CY; Lin SM; Sheen IS
J Formos Med Assoc; 2024 Jul; 123(7):788-795. PubMed ID: 38310071
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
[TBL] [Abstract][Full Text] [Related]
5. Prognostic PET [
Chiu KWH; Tan KV; Yang X; Zhu X; Shi J; Chiang CL; Chan L; Hui Y; Khong PL; Man K; Wong JWH
Cancer Imaging; 2024 Mar; 24(1):42. PubMed ID: 38520026
[TBL] [Abstract][Full Text] [Related]
6. Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Piscaglia F; Ikeda K; Cheng AL; Kudo M; Ikeda M; Breder V; Ryoo BY; Mody K; Ren M; Ramji Z; Sung MW
Cancer; 2024 Apr; 130(8):1281-1291. PubMed ID: 38261521
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.
Ueno M; Ikeda M; Sasaki T; Nagashima F; Mizuno N; Shimizu S; Ikezawa H; Hayata N; Nakajima R; Morizane C
BMC Cancer; 2020 Nov; 20(1):1105. PubMed ID: 33198671
[TBL] [Abstract][Full Text] [Related]
8. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
Liu Z; Li X; He X; Xu Y; Wang X
BMC Cancer; 2019 Nov; 19(1):1062. PubMed ID: 31703571
[TBL] [Abstract][Full Text] [Related]
9. Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed.
Yang S; Liang H; Li X; Qian J; Ming Z
Hepatol Int; 2024 Jun; 18(3):1058-1059. PubMed ID: 38717694
[No Abstract] [Full Text] [Related]
10. Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
Niho S; Sato J; Satouchi M; Itoh S; Okuma Y; Mizugaki H; Murakami H; Fujisaka Y; Kozuki T; Nakamura K; Machida R; Ohe Y; Tamai T; Ikezawa H; Yamamoto N
Lung Cancer; 2024 May; 191():107557. PubMed ID: 38626709
[TBL] [Abstract][Full Text] [Related]
11. Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma.
Okuno M; Hatano E; Tada M; Nishimura T; Okamoto T; Sueoka H; Iida K; Nakamura I; Iijima H; Hirono S
Anticancer Res; 2024 Apr; 44(4):1727-1737. PubMed ID: 38537993
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
Camera S; Rimini M; Rossari F; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Salani F; Marseglia M; Amadeo E; Vitiello F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Iavarone M; Cabibbo G; Montes M; Foschi FG; Vivaldi C; Lonardi S; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Hiraoka A; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Persano M; Foti S; Piscaglia F; Scartozzi M; Cascinu S; Casadei-Gardini A
Target Oncol; 2024 Jan; 19(1):29-39. PubMed ID: 38252195
[TBL] [Abstract][Full Text] [Related]
13. Complete tumor response after concomitant treatment with lenvatinib and radioembolization with Ytrio-90 of advanced stage hepatocarcinoma.
Martínez Benito B; González Pintor V; Del Campo Del Val L; García-Buey L
Gastroenterol Hepatol; 2024; 47(6):620-622. PubMed ID: 37742831
[No Abstract] [Full Text] [Related]
14. Systematic review of the efficacy and safety of lenvatinib in various solid tumors.
Geng S; Liu T; Wang N; Gao X; Luo X; Shi N; Jiang S
Immunopharmacol Immunotoxicol; 2024 Jun; 46(3):395-407. PubMed ID: 38627024
[TBL] [Abstract][Full Text] [Related]
15. EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma.
Lim M; Franses JW; Imperial R; Majeed U; Tsai J; Hsiehchen D
Gastroenterology; 2023 May; 164(6):1006-1008.e3. PubMed ID: 36708791
[No Abstract] [Full Text] [Related]
16. PET imaging with FAPI-ligands for non-cirrhotic hepatocellular carcinoma.
Lee Z; Lu ZR; Sexton S; Xin W
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3190-3191. PubMed ID: 37405467
[No Abstract] [Full Text] [Related]
17. Role of textural analysis parameters derived from FDG PET/CT in differentiating hepatocellular carcinoma and hepatic metastases: Erratum.
Nucl Med Commun; 2024 Apr; 45(4):353. PubMed ID: 38446124
[No Abstract] [Full Text] [Related]
18. Pretreatment Photopenia on 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Scans Predicts Poor Prognosis in Nasopharyngeal Cancer Patients Undergoing Concurrent Chemoradiotherapy.
Topkan E; Selek U; Mertsoylu H; Ozdemir Y; Kucuk A; Torun N; Besen AA
Clin Exp Otorhinolaryngol; 2020 Nov; 13(4):407-414. PubMed ID: 32075362
[TBL] [Abstract][Full Text] [Related]
19. A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration.
Yano R; Hirooka M; Nakamura Y; Imai Y; Koizumi Y; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
Clin J Gastroenterol; 2024 Apr; 17(2):319-326. PubMed ID: 38281290
[TBL] [Abstract][Full Text] [Related]
20. Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial-level analysis.
Colloca GA; Venturino A
Cancer; 2024 May; 130(10):1773-1783. PubMed ID: 38231887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
